Skip to main content
Top
Published in: Inflammation 2/2014

01-04-2014

Genetic Susceptibility to Nosocomial Pneumonia, Acute Respiratory Distress Syndrome and Poor Outcome in Patients at Risk of Critical Illness

Authors: Lyubov E. Salnikova, Tamara V. Smelaya, Irina N. Vesnina, Arkadiy M. Golubev, Viktor V. Moroz

Published in: Inflammation | Issue 2/2014

Login to get access

Abstract

Genetic susceptibility may partially explain the clinical variability observed during the course of similar infections. To establish the contribution of genetic host factors in the susceptibility to critical illness, we genotyped 750 subjects (419 at high risk of critical illness) for 14 single nucleotide polymorphisms (SNPs) in the xenobiotics detoxification/oxidative stress and vascular homeostasis metabolic pathways. In the group of nosocomial pneumonia (NP; 268 patients) the risk of acute respiratory distress syndrome (ARDS) is significantly higher for the carriers of CYP1A1 rs2606345 T/T genotypes and AhR rs2066853 G/A-A/A genotypes. AGTR1 rs5186 allele C is more common among NP non-survivors. The duration of stay in intensive care units (ICU) is higher for NP patients with ABCB1 rs1045642-T allele. The cumulative effect of the risk alleles in the genes comprising two sets of genes partners (xenobiotics detoxification: CYP1A1, AhR and RAS family: ACE, AGT, AGTR1) is associated with the development of both NP and ARDS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yoon, Y.S. 2012. Respiratory review of 2012: Pneumonia. Tuberculosis and Respiratory Diseases (Seoul) 73(2): 77–83.CrossRef Yoon, Y.S. 2012. Respiratory review of 2012: Pneumonia. Tuberculosis and Respiratory Diseases (Seoul) 73(2): 77–83.CrossRef
2.
go back to reference Angus, D.C., D. Burgner, R. Wunderink, J.P. Mira, H. Gerlach, C.J. Wiedermann, and J.L. Vincent. 2003. The PIRO concept: P is for predisposition. Critical Care 7: 248–251.PubMedCentralPubMedCrossRef Angus, D.C., D. Burgner, R. Wunderink, J.P. Mira, H. Gerlach, C.J. Wiedermann, and J.L. Vincent. 2003. The PIRO concept: P is for predisposition. Critical Care 7: 248–251.PubMedCentralPubMedCrossRef
3.
go back to reference Kumpf, O., E.J. Giamarellos-Bourboulis, A. Koch, L. Hamann, M. Mouktaroudi, D.Y. Oh, et al. 2010. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: An observational study in three cohorts. Critical Care 14(3): R103.PubMedCentralPubMedCrossRef Kumpf, O., E.J. Giamarellos-Bourboulis, A. Koch, L. Hamann, M. Mouktaroudi, D.Y. Oh, et al. 2010. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: An observational study in three cohorts. Critical Care 14(3): R103.PubMedCentralPubMedCrossRef
4.
go back to reference Jerng, J.S., C.J. Yu, H.C. Wang, K.Y. Chen, S.L. Cheng, and P.C. Yang. 2006. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Critical Care Medicine 34(4): 1001–1006.PubMedCrossRef Jerng, J.S., C.J. Yu, H.C. Wang, K.Y. Chen, S.L. Cheng, and P.C. Yang. 2006. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Critical Care Medicine 34(4): 1001–1006.PubMedCrossRef
5.
go back to reference Hedberg, C.L., K. Adcock, J. Martin, J. Loggins, T.E. Kruger, and R.J. Baier. 2004. Tumor necrosis factor alpha — 308 polymorphism associated with increased sepsis mortality in ventilated very low birth weight infants. Pediatric Infectious Disease Journal 23(5): 424–428.PubMedCrossRef Hedberg, C.L., K. Adcock, J. Martin, J. Loggins, T.E. Kruger, and R.J. Baier. 2004. Tumor necrosis factor alpha — 308 polymorphism associated with increased sepsis mortality in ventilated very low birth weight infants. Pediatric Infectious Disease Journal 23(5): 424–428.PubMedCrossRef
6.
go back to reference Kotsaki, A., M. Raftogiannis, C. Routsi, F. Baziaka, A. Kotanidou, A. Antonopoulou, et al. 2012. Genetic polymorphisms within tumor necrosis factor gene promoter region: A role for susceptibility to ventilator-associated pneumonia. Cytokine 59(2): 358–363.PubMedCrossRef Kotsaki, A., M. Raftogiannis, C. Routsi, F. Baziaka, A. Kotanidou, A. Antonopoulou, et al. 2012. Genetic polymorphisms within tumor necrosis factor gene promoter region: A role for susceptibility to ventilator-associated pneumonia. Cytokine 59(2): 358–363.PubMedCrossRef
7.
go back to reference Madách, K., I. Aladzsity, A. Szilágyi, G. Fust, J. Gál, I. Pénzes, and Z. Prohászka. 2010. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: Prospective, observational, genetic study. Critical Care 14(2): R79.PubMedCentralPubMedCrossRef Madách, K., I. Aladzsity, A. Szilágyi, G. Fust, J. Gál, I. Pénzes, and Z. Prohászka. 2010. 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: Prospective, observational, genetic study. Critical Care 14(2): R79.PubMedCentralPubMedCrossRef
8.
go back to reference Salnikova, L.E., T.V. Smelaya, V.V. Moroz, A.M. Golubev, and A.V. Rubanovich. 2013. Host genetic risk factors for community-acquired pneumonia. Gene 518(2): 449–456.PubMedCrossRef Salnikova, L.E., T.V. Smelaya, V.V. Moroz, A.M. Golubev, and A.V. Rubanovich. 2013. Host genetic risk factors for community-acquired pneumonia. Gene 518(2): 449–456.PubMedCrossRef
9.
go back to reference Salnikova, L.E., T.V. Smelaya, V.V. Moroz, A.M. Golubev, and A.V. Rubanovich. 2013. Functional polymorphisms in the CYP1A1, ACE, and IL-6 genes contribute to susceptibility to community-acquired and nosocomial pneumonia. International Journal of Infectious Diseases 17(6): e433–e442.PubMedCrossRef Salnikova, L.E., T.V. Smelaya, V.V. Moroz, A.M. Golubev, and A.V. Rubanovich. 2013. Functional polymorphisms in the CYP1A1, ACE, and IL-6 genes contribute to susceptibility to community-acquired and nosocomial pneumonia. International Journal of Infectious Diseases 17(6): e433–e442.PubMedCrossRef
10.
go back to reference Fine, M.J., T.E. Auble, D.M. Yealy, B.H. Hanusa, L.A. Weissfeld, D.E. Singer, et al. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 336(4): 243–250.PubMedCrossRef Fine, M.J., T.E. Auble, D.M. Yealy, B.H. Hanusa, L.A. Weissfeld, D.E. Singer, et al. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 336(4): 243–250.PubMedCrossRef
11.
go back to reference Levy, M.M., M.P. Fink, J.C. Marshall, E. Abraham, D. Angus, D. Cook, et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Critical Care Medicine 31(4): 1250–1256.PubMedCrossRef Levy, M.M., M.P. Fink, J.C. Marshall, E. Abraham, D. Angus, D. Cook, et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Critical Care Medicine 31(4): 1250–1256.PubMedCrossRef
12.
go back to reference Hamajima, N. 2001. PCR–CTPP: A new genotyping technique in the era of genetic epidemiology. Expert Review of Molecular Diagnostics 1(1): 119–123.PubMedCrossRef Hamajima, N. 2001. PCR–CTPP: A new genotyping technique in the era of genetic epidemiology. Expert Review of Molecular Diagnostics 1(1): 119–123.PubMedCrossRef
13.
go back to reference Sole, X., E. Guino, J. Valls, R. Iniesta, and V. Moreno. 2006. SNPStats: A web tool for the analysis of association studies. Bioinformatics 22(15): 1928–1929.PubMedCrossRef Sole, X., E. Guino, J. Valls, R. Iniesta, and V. Moreno. 2006. SNPStats: A web tool for the analysis of association studies. Bioinformatics 22(15): 1928–1929.PubMedCrossRef
14.
go back to reference Abramson, J.H. 2011. WINPEPI updated: Computer programs for epidemiologists, and their teaching potential. Epidemiologic Perspectives & Innovations 8: 1.CrossRef Abramson, J.H. 2011. WINPEPI updated: Computer programs for epidemiologists, and their teaching potential. Epidemiologic Perspectives & Innovations 8: 1.CrossRef
15.
go back to reference Jiang, W., S.E. Welty, X.I. Couroucli, R. Barrios, S.R. Kondraganti, K. Muthiah, et al. 2004. Disruption of the Ah receptor gene alters the susceptibility of mice to oxygen-mediated regulation of pulmonary and hepatic cytochromes P4501A expression and exacerbates hyperoxic lung injury. Journal of Pharmacology and Experimental Therapeutics 310(2): 512–519.PubMedCrossRef Jiang, W., S.E. Welty, X.I. Couroucli, R. Barrios, S.R. Kondraganti, K. Muthiah, et al. 2004. Disruption of the Ah receptor gene alters the susceptibility of mice to oxygen-mediated regulation of pulmonary and hepatic cytochromes P4501A expression and exacerbates hyperoxic lung injury. Journal of Pharmacology and Experimental Therapeutics 310(2): 512–519.PubMedCrossRef
16.
go back to reference Jiang, W., X.I. Couroucli, L. Wang, R. Barrios, and B. Moorthy. 2011. Augmented oxygen-mediated transcriptional activation of cytochrome P450 (CYP)1A expression and increased susceptibilities to hyperoxic lung injury in transgenic mice carrying the human CYP1A1 or mouse 1A2 promoter in vivo. Biochemical and Biophysical Research Communications 407(1): 79–85.PubMedCentralPubMedCrossRef Jiang, W., X.I. Couroucli, L. Wang, R. Barrios, and B. Moorthy. 2011. Augmented oxygen-mediated transcriptional activation of cytochrome P450 (CYP)1A expression and increased susceptibilities to hyperoxic lung injury in transgenic mice carrying the human CYP1A1 or mouse 1A2 promoter in vivo. Biochemical and Biophysical Research Communications 407(1): 79–85.PubMedCentralPubMedCrossRef
17.
go back to reference Rotunno, M., K. Yu, J.H. Lubin, D. Consonni, A.C. Pesatori, et al. 2009. Phase I metabolic genes and risk of lung cancer: Multiple polymorphisms and mRNA expression. PLoS One 4(5): e5652.PubMedCentralPubMedCrossRef Rotunno, M., K. Yu, J.H. Lubin, D. Consonni, A.C. Pesatori, et al. 2009. Phase I metabolic genes and risk of lung cancer: Multiple polymorphisms and mRNA expression. PLoS One 4(5): e5652.PubMedCentralPubMedCrossRef
18.
go back to reference Wang, S., S. Chanock, D. Tang, Z. Li, W. Jedrychowski, and F.P. Perera. 2008. Assessment of interactions between PAH exposure and genetic polymorphisms on PAH- DNA adducts in African American, Dominican and Caucasian mothers and newborns. Cancer Epidemiology, Biomarkers and Prevention 17(2): 405–413.PubMedCentralPubMedCrossRef Wang, S., S. Chanock, D. Tang, Z. Li, W. Jedrychowski, and F.P. Perera. 2008. Assessment of interactions between PAH exposure and genetic polymorphisms on PAH- DNA adducts in African American, Dominican and Caucasian mothers and newborns. Cancer Epidemiology, Biomarkers and Prevention 17(2): 405–413.PubMedCentralPubMedCrossRef
19.
go back to reference Zhang, B., A. Beeghly-Fadiel, W. Lu, Q. Cai, Y.B. Xiang, Y. Zheng, et al. 2011. Evaluation of functional genetic variants for breast cancer risk: Results from the Shanghai breast cancer study. American Journal of Epidemiology 173(10): 1159–1170.PubMedCentralPubMedCrossRef Zhang, B., A. Beeghly-Fadiel, W. Lu, Q. Cai, Y.B. Xiang, Y. Zheng, et al. 2011. Evaluation of functional genetic variants for breast cancer risk: Results from the Shanghai breast cancer study. American Journal of Epidemiology 173(10): 1159–1170.PubMedCentralPubMedCrossRef
20.
go back to reference Denison, M.S., and S.R. Nagy. 2003. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annual Review of Pharmacology and Toxicology 43: 309–334.PubMedCrossRef Denison, M.S., and S.R. Nagy. 2003. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annual Review of Pharmacology and Toxicology 43: 309–334.PubMedCrossRef
21.
go back to reference Busbee, P.B., M. Rouse, M. Nagarkatti, and P.S. Nagarkatti. 2013. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutrition Reviews 71(6): 353–369.PubMedCrossRef Busbee, P.B., M. Rouse, M. Nagarkatti, and P.S. Nagarkatti. 2013. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutrition Reviews 71(6): 353–369.PubMedCrossRef
23.
go back to reference Rohlman, D., D. Pham, Z. Yu, L.B. Steppan, and N.I. Kerkvliet. 2012. Aryl hydrocarbon receptor-mediated perturbations in gene expression during early stages of CD4(+) T-cell differentiation. Frontiers in Immunology 3: 223.PubMedCentralPubMedCrossRef Rohlman, D., D. Pham, Z. Yu, L.B. Steppan, and N.I. Kerkvliet. 2012. Aryl hydrocarbon receptor-mediated perturbations in gene expression during early stages of CD4(+) T-cell differentiation. Frontiers in Immunology 3: 223.PubMedCentralPubMedCrossRef
24.
go back to reference Esser, C., A. Rannug, and B. Stockinger. 2004. The aryl hydrocarbon receptor in immunity. Trends in Immunology Journal of Pharmacology and Experimental Therapeutics 310(2): 512–519.CrossRef Esser, C., A. Rannug, and B. Stockinger. 2004. The aryl hydrocarbon receptor in immunity. Trends in Immunology Journal of Pharmacology and Experimental Therapeutics 310(2): 512–519.CrossRef
25.
go back to reference Gradman, E.H. 2009. Evolving understanding of the renin–angiotensin–aldosterone system: Pathophysiology and targets for therapeutic intervention. American Heart Journal 157: S1–S6.PubMedCrossRef Gradman, E.H. 2009. Evolving understanding of the renin–angiotensin–aldosterone system: Pathophysiology and targets for therapeutic intervention. American Heart Journal 157: S1–S6.PubMedCrossRef
26.
go back to reference Rajagopalan, S., S. Kurz, T. Munzel, M. Tarpey, B.A. Freeman, K.K. Griendling, and D.G. Harrison. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. Journal of Clinical Investigation 97: 1916–1923.PubMedCentralPubMedCrossRef Rajagopalan, S., S. Kurz, T. Munzel, M. Tarpey, B.A. Freeman, K.K. Griendling, and D.G. Harrison. 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. Journal of Clinical Investigation 97: 1916–1923.PubMedCentralPubMedCrossRef
27.
go back to reference Manzanares, W., R. Dhaliwal, X. Jiang, L. Murch, and D.K. Heyland. 2012. Antioxidant micronutrients in the critically ill: A systematic review and meta-analysis. Critical Care 16(2): R66.PubMedCentralPubMedCrossRef Manzanares, W., R. Dhaliwal, X. Jiang, L. Murch, and D.K. Heyland. 2012. Antioxidant micronutrients in the critically ill: A systematic review and meta-analysis. Critical Care 16(2): R66.PubMedCentralPubMedCrossRef
28.
go back to reference Zhou, M.S., I.H. Schulman, and L. Raij. 2004. Nitric oxide, angiotensin II, and hypertension. Seminars in Nephrology 24: 366–378.PubMedCrossRef Zhou, M.S., I.H. Schulman, and L. Raij. 2004. Nitric oxide, angiotensin II, and hypertension. Seminars in Nephrology 24: 366–378.PubMedCrossRef
29.
go back to reference Martin, M.M., J.A. Buckenberger, J. Jiang, G.E. Malana, G.J. Nuovo, M. Chotani, et al. 2007. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. Journal of Biological Chemistry 282(33): 24262–24269.PubMedCentralPubMedCrossRef Martin, M.M., J.A. Buckenberger, J. Jiang, G.E. Malana, G.J. Nuovo, M. Chotani, et al. 2007. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. Journal of Biological Chemistry 282(33): 24262–24269.PubMedCentralPubMedCrossRef
30.
go back to reference Wu, C.K., C.T. Tsai, Y.C. Chang, J.L. Luo, Y.C. Wang, J.J. Hwang, et al. 2009. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. Journal of Hypertension 27(3): 502–507.PubMedCrossRef Wu, C.K., C.T. Tsai, Y.C. Chang, J.L. Luo, Y.C. Wang, J.J. Hwang, et al. 2009. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. Journal of Hypertension 27(3): 502–507.PubMedCrossRef
31.
go back to reference Zhang, K., B. Zhou, and L. Zhang. 2013. Association study of angiotensin II type 1 receptor: A1166C (rs5186) polymorphism with coronary heart disease using systematic meta-analysis. Journal of the Renin-Angiotensin-Aldosterone System 14(2): 181–188.PubMedCrossRef Zhang, K., B. Zhou, and L. Zhang. 2013. Association study of angiotensin II type 1 receptor: A1166C (rs5186) polymorphism with coronary heart disease using systematic meta-analysis. Journal of the Renin-Angiotensin-Aldosterone System 14(2): 181–188.PubMedCrossRef
32.
go back to reference Cameron, V.A., T.J. Mocatta, A.P. Pilbrow, C.M. Frampton, R.W. Troughton, A.M. Richards, et al. 2006. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47: 1155–1161.PubMedCrossRef Cameron, V.A., T.J. Mocatta, A.P. Pilbrow, C.M. Frampton, R.W. Troughton, A.M. Richards, et al. 2006. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47: 1155–1161.PubMedCrossRef
33.
go back to reference Ho, R.H., and R.B. Kim. 2005. Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 78: 260–277.PubMedCrossRef Ho, R.H., and R.B. Kim. 2005. Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 78: 260–277.PubMedCrossRef
34.
go back to reference Zhou, S.F. 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38(7–8): 802–832.PubMedCrossRef Zhou, S.F. 2008. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38(7–8): 802–832.PubMedCrossRef
35.
go back to reference Fernandez, C., M. Buyse, M. German-Fattal, and F. Gimenez. 2004. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. Journal of Pharmacy and Pharmaceutical Sciences 7(3): 359–371.PubMed Fernandez, C., M. Buyse, M. German-Fattal, and F. Gimenez. 2004. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. Journal of Pharmacy and Pharmaceutical Sciences 7(3): 359–371.PubMed
36.
go back to reference Kimchi-Sarfaty, C., J.M. Oh, I.-W. Kim, Z.E. Sauna, A.M. Calcagno, S.V. Ambudkar, et al. 2007. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525–528.PubMedCrossRef Kimchi-Sarfaty, C., J.M. Oh, I.-W. Kim, Z.E. Sauna, A.M. Calcagno, S.V. Ambudkar, et al. 2007. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525–528.PubMedCrossRef
37.
go back to reference Markova, S., T. Nakamura, T. Sakaeda, H. Makimoto, H. Uchiyama, N. Okamura, and K. Okumura. 2006. Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metabolism and Pharmacokinetics 21(3): 194–200.PubMedCrossRef Markova, S., T. Nakamura, T. Sakaeda, H. Makimoto, H. Uchiyama, N. Okamura, and K. Okumura. 2006. Genotype-dependent down-regulation of gene expression and function of MDR1 in human peripheral blood mononuclear cells under acute inflammation. Drug Metabolism and Pharmacokinetics 21(3): 194–200.PubMedCrossRef
38.
go back to reference Weng, L., F. Macciardi, A. Subramanian, G. Guffanti, S.G. Potkin, Z. Yu, and X. Xie. 2011. SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinformatics 12: 99.PubMedCentralPubMedCrossRef Weng, L., F. Macciardi, A. Subramanian, G. Guffanti, S.G. Potkin, Z. Yu, and X. Xie. 2011. SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinformatics 12: 99.PubMedCentralPubMedCrossRef
39.
40.
go back to reference Tsantes, A.E., Kopterides, P., Bonovas, S., Bagos, P., Antonakos, G., Nikolopoulos, G.K., et al. 2013. The effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiol 2013. Tsantes, A.E., Kopterides, P., Bonovas, S., Bagos, P., Antonakos, G., Nikolopoulos, G.K., et al. 2013. The effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiol 2013.
41.
go back to reference Camós, S., M.J. Cruz, F. Morell, and E. Solé. 2012. Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish population sample. Clinical Chemistry and Laboratory Medicine 50(10): 1749–1753.PubMedCrossRef Camós, S., M.J. Cruz, F. Morell, and E. Solé. 2012. Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish population sample. Clinical Chemistry and Laboratory Medicine 50(10): 1749–1753.PubMedCrossRef
42.
go back to reference Takahashi, T., S. Morimoto, K. Okaishi, T. Kanda, T. Nakahashi, M. Okuro, et al. 2005. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene. American Journal of Hypertension 18(10): 1353–1359.PubMedCrossRef Takahashi, T., S. Morimoto, K. Okaishi, T. Kanda, T. Nakahashi, M. Okuro, et al. 2005. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene. American Journal of Hypertension 18(10): 1353–1359.PubMedCrossRef
43.
go back to reference Sethi, A.A., B.G. Nordestgaard, and A. Tybjaerg-Hansen. 2003. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arteriosclerosis, Thrombosis, and Vascular Biology 23(7): 1269–1275.PubMedCrossRef Sethi, A.A., B.G. Nordestgaard, and A. Tybjaerg-Hansen. 2003. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arteriosclerosis, Thrombosis, and Vascular Biology 23(7): 1269–1275.PubMedCrossRef
44.
go back to reference Orfanos, S.E., A. Armaganidis, C. Glynos, E. Psevdi, P. Kaltsasm, P. Sarafidou, et al. 2000. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 102(16): 2011–2018.PubMedCrossRef Orfanos, S.E., A. Armaganidis, C. Glynos, E. Psevdi, P. Kaltsasm, P. Sarafidou, et al. 2000. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 102(16): 2011–2018.PubMedCrossRef
Metadata
Title
Genetic Susceptibility to Nosocomial Pneumonia, Acute Respiratory Distress Syndrome and Poor Outcome in Patients at Risk of Critical Illness
Authors
Lyubov E. Salnikova
Tamara V. Smelaya
Irina N. Vesnina
Arkadiy M. Golubev
Viktor V. Moroz
Publication date
01-04-2014
Publisher
Springer US
Published in
Inflammation / Issue 2/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9740-x

Other articles of this Issue 2/2014

Inflammation 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.